NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球焦慮和憂鬱治療市場:按產品類型、殘疾類型、分銷渠道行業分析和需求預測(至 2030 年)

Anxiety and Depression Treatment Market Research Report: By Product Type, Disorder Type, Distribution Channel - Global Industry Analysis and Demand Forecast to 2030

出版商 Prescient & Strategic Intelligence Private Limited 商品編碼 1007633
出版日期 內容資訊 英文 369 Pages
商品交期: 2-3個工作天內
價格
全球焦慮和憂鬱治療市場:按產品類型、殘疾類型、分銷渠道行業分析和需求預測(至 2030 年) Anxiety and Depression Treatment Market Research Report: By Product Type, Disorder Type, Distribution Channel - Global Industry Analysis and Demand Forecast to 2030
出版日期: 2021年03月01日內容資訊: 英文 369 Pages
簡介

2020 年全球焦慮和憂鬱治療市場的銷售額達到 177.709 億美元。預計該市場在 2021 年至 2030 年間將以 3.3% 的複合年增長率增長,到 2030 年達到 244.677 億美元。

COVID-19 大流行對焦慮症和憂鬱症藥物市場產生了負面影響。世界各地的封鎖已經關閉了工廠並減少了藥品和設備的生產。此外,這些產品的供應因不必要的緊急運輸和受限制的國際貿易而受到限制。

本報告調查了全球焦慮症/憂鬱症治療市場、市場規模和預測、機會、增長和抑制因素、按產品類型/殘疾類型/分銷渠道/地區劃分的市場分析,提供了諸如競爭狀況和大公司簡介。

目錄

第 1 章調查背景

  • 調查目的
  • 市場定義
  • 分析期
  • 市場數據報告單位
    • 銷售
  • 按細分市場劃分的市場規模
    • 按產品類型細分市場
    • 按殘疾類型細分藥品市場
    • 按分銷渠道細分醫藥市場
    • 按地區劃分的市場細分
  • 主要利益相關者

第 2 章調查方法

  • 二次調查
  • 初步調查
  • 估計市場規模
  • 數據三角剖分
  • 匯率
  • 注意事項和警告

第 3 章執行摘要

第 4 章行業專家/KOL之聲

第 5 章市場指標

  • 精神障礙的患病率

第 6 章細分市場的定義

  • 產品類型
    • 藥物
      • 抗憂鬱藥
      • 抗驚厥藥
      • 非典型抗精神病藥
      • 苯二氮卓類
      • Beta 攔截器
    • 設備
  • 按故障類型
    • 重度憂鬱症
    • 強迫症
    • 恐懼症
    • 創傷後應激障礙
    • 其他
  • 按分銷渠道
    • 醫院藥房
    • 零售藥店
    • 在線渠道
    • 直接渠道

第 7 章行業展望

  • 市場動態
    • 趨勢
      • 併購增加
    • 增長因素
      • 人口老齡化加劇
      • 提高對精神疾病及其治療的認識
      • 產品審批數量增加
      • 增長因素對市場預測的影響分析
    • 抑制因素
      • 與使用藥物和設備相關的副作用
      • 補充和替代醫學的可用性
      • 制約因素對市場預測的影響分析
    • 市場機會
      • 新興經濟體,市場企業的重要機遇領域
  • COVID-19 的影響
  • 波特五力分析

第 8 章全球市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)
  • 按地區劃分的市場收入(2015-2030 年)

第 9 章北美市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)
  • 按國家/地區劃分的市場收入(2015-2030 年)

第 10 章歐洲市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)
  • 按國家/地區劃分的市場收入(2015-2030 年)

第 11 章亞太市場規模及預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)
  • 按國家/地區劃分的市場收入(2015-2030 年)

第 12 章拉丁美洲市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)
  • 按國家/地區劃分的市場收入(2015-2030 年)

第 13 章中東/非洲市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)
  • 按國家/地區劃分的市場收入(2015-2030 年)

第 14 章美國市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 15 章加拿大市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 16 章德國市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 17 章法國市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 18 章英國市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 19 章意大利市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 20 章西班牙市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 21 章中國市場規模及預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 22 章日本市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 23 章印度市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗 藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 24 章澳大利亞市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗 藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 25 章韓國市場規模及預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗 藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 26 章巴西市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 27 章墨西哥市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 28 章沙特阿拉伯市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 29 章南非市場規模和預測

  • 概述
  • 按產品類型:市場收入(2015-2030)
    • 按類型劃分的醫藥市場收入(2015-2030 年)
      • 按類型:抗憂鬱藥市場收入(2015-2030 年)
    • 按殘疾類型劃分的醫藥市場收入(2015-2030 年)
    • 按分銷渠道劃分的醫藥市場收入(2015-2030 年)

第 30 章競爭形勢

  • 上市公司及其產品清單
  • 產品基準
  • 各大公司近期戰略發展
    • 產品發佈和審批
    • 併購
    • 其他

第 31 章公司簡介

  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Sanofi
  • H. Lundbeck A/S
  • Mylan N.V.
  • Cipla Ltd.
  • Glenmark Life Sciences Limited
  • Lupin Limited
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca plc
  • Sun Pharmaceutical Industries Ltd.
  • Intas Pharmaceuticals Ltd.
  • Sumitomo Dainippon Pharma Co. Ltd.

第 32 章附錄

  • 縮寫
  • 來源和參考資料
  • 相關報導
目錄
Product Code: LS12173

The World Health Organization (WHO) has designated October 10th as World Mental Health Day in order to raise awareness about such issues and lessen people's hesitation in seeking treatment. As a result of such initiatives, the global anxiety and depression treatment market value is predicted to increase from $17,770.9 million in 2020 to $24,467.7 million by 2030, at a 3.3% CAGR between 2021 and 2030, according to the market research report published by P&S Intelligence.

Similarly, a program, named Better Outcomes in Mental Health Care (BOiMHC), and an organization, called Mental Health Association, have been formed to help the cause in Australia. Another such organization aiding the anxiety and depression treatment market growth with its support to patients and educational courses is the National Alliance on Mental Illness (NAMI), which was founded in the U.S. in 1979.

Due to the COVID-19 pandemic, the anxiety and depression treatment market reported negative impact. The lockdowns implemented around the world led to the shutting down of factories, which resulted in the low production of drugs and devices. Moreover, the restrictions on non-essential movement and international trade led to the curtailed supply of such products.

The highest CAGR in the anxiety and depression drugs market in the years to come is expected to be witnessed in the online channels category, on the basis of distribution channel. Because of the shopping convenience offered by such websites, allowing people to order from home, avail discounts, and receive doorstep delivery, customers are switching to them.

Presently, North America generates the highest revenue in the anxiety and depression treatment market due to the rising incidence of chronic pain, anxiety, and depression, increasing awareness regarding mental health, and growing number of people receiving prescriptions for the associated drugs and devices. In the years to come, the demand for such products will shoot up the fastest in Asia-Pacific (APAC). The prevalence of anxiety and depression is rising in the region owing to the booming population of the elderly.

Major companies in the global anxiety and depression treatment market are Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Johnson & Johnson, AbbVie Inc., Merck & Co. Inc., Eli Lilly and Company, Sanofi, Lundbeck A/S, GlaxoSmithKline plc, Mylan N.V, Glenmark Life Sciences Limited, Cipla Ltd., Lupin Limited, AstraZeneca plc, Amneal Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., and Intas Pharmaceuticals Ltd.

Table of Contents

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Analysis Period
  • 1.4 Market Data Reporting Unit
    • 1.4.1 Value
  • 1.5 Market Size Breakdown by Segment
    • 1.5.1 Market Segmentation by Product Type
    • 1.5.2 Drugs Market Segmentation by Disorder Type
    • 1.5.3 Drugs Market Segmentation by Distribution Channel
    • 1.5.4 Market Segmentation by Region
  • 1.6 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
    • 2.1.1 Paid
    • 2.1.2 Unpaid
    • 2.1.3 P&S Intelligence Database
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research, by Region
    • 2.2.2 Breakdown of Primary Research, by Industry Participant
    • 2.2.3 Breakdown of Primary Research, by Company Type
  • 2.3 Market Size Estimation
  • 2.4 Data Triangulation
  • 2.5 Currency Conversion Rates
  • 2.6 Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

  • 5.1 Prevalence of Mental Disorders

Chapter 6. Definition of Market Segments

  • 6.1 By Product Type
    • 6.1.1 Drugs
      • 6.1.1.1 Antidepressants
        • 6.1.1.1.1 SSRIs
        • 6.1.1.1.2 SNRIs
        • 6.1.1.1.3 TCAs
        • 6.1.1.1.4 MAOIs
        • 6.1.1.1.5 Others
      • 6.1.1.2 Anticonvulsants
      • 6.1.1.3 Atypical antipsychotics
      • 6.1.1.4 Benzodiazepines
      • 6.1.1.5 Beta-blockers
    • 6.1.2 Devices
  • 6.2 By Disorder Type
    • 6.2.1 Major Depressive Disorder
    • 6.2.2 OCD
    • 6.2.3 Phobia
    • 6.2.4 PTSD
    • 6.2.5 Others
  • 6.3 By Distribution Channel
    • 6.3.1 Hospital Pharmacies
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Channels
    • 6.3.4 Direct Channels

Chapter 7. Industry Outlook

  • 7.1 Market Dynamics
    • 7.1.1 Trends
      • 7.1.1.1 Increasing number of mergers and acquisitions
    • 7.1.2 Drivers
      • 7.1.2.1 Increasing aging population
      • 7.1.2.2 Growing awareness about mental diseases and their treatment
      • 7.1.2.3 Rising number of product approvals
      • 7.1.2.4 Impact analysis of drivers on market forecast
    • 7.1.3 Restraints
      • 7.1.3.1 Side effects associated with usage of drugs and devices
      • 7.1.3.2 Availability of complementary and alternative medicines
      • 7.1.3.3 Impact analysis of restraints on market forecast
    • 7.1.4 Opportunities
      • 7.1.4.1 Emerging economies are key opportunity areas for market players
  • 7.2 Impact of COVID-19
  • 7.3 Porter's Five Forces Analysis
    • 7.3.1 Bargaining Power of Buyers
    • 7.3.2 Bargaining Power of Suppliers
    • 7.3.3 Intensity of Rivalry
    • 7.3.4 Threat of New Entrants
    • 7.3.5 Threat of Substitutes

Chapter 8. Global Market Size and Forecast

  • 8.1 Overview
  • 8.2 Market Revenue, by Product Type (2015-2030)
    • 8.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 8.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 8.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 8.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)
  • 8.3 Market Revenue, by Region (2015-2030)

Chapter 9. North America Market Size and Forecast

  • 9.1 Overview
  • 9.2 Market Revenue, by Product Type (2015-2030)
    • 9.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 9.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 9.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 9.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)
  • 9.3 Market Revenue, by Country (2015-2030)

Chapter 10. Europe Market Size and Forecast

  • 10.1 Overview
  • 10.2 Market Revenue, by Product Type (2015-2030)
    • 10.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 10.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 10.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 10.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)
  • 10.3 Market Revenue, by Country (2015-2030)

Chapter 11. APAC Market Size and Forecast

  • 11.1 Overview
  • 11.2 Market Revenue, by Product Type (2015-2030)
    • 11.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 11.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 11.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 11.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)
  • 11.3 Market Revenue, by Country (2015-2030)

Chapter 12. LATAM Market Size and Forecast

  • 12.1 Overview
  • 12.2 Market Revenue, by Product Type (2015-2030)
    • 12.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 12.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 12.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 12.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)
  • 12.3 Market Revenue, by Country (2015-2030)

Chapter 13. MEA Market Size and Forecast

  • 13.1 Overview
  • 13.2 Market Revenue, by Product Type (2015-2030)
    • 13.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 13.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 13.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 13.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)
  • 13.3 Market Revenue, by Country (2015-2030)

Chapter 14. U.S. Market Size and Forecast

  • 14.1 Overview
  • 14.2 Market Revenue, by Product Type (2015-2030)
    • 14.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 14.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 14.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 14.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 15. Canada Market Size and Forecast

  • 15.1 Overview
  • 15.2 Market Revenue, by Product Type (2015-2030)
    • 15.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 15.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 15.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 15.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 16. Germany Market Size and Forecast

  • 16.1 Overview
  • 16.2 Market Revenue, by Product Type (2015-2030)
    • 16.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 16.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 16.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 16.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 17. France Market Size and Forecast

  • 17.1 Overview
  • 17.2 Market Revenue, by Product Type (2015-2030)
    • 17.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 17.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 17.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 17.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 18. U.K. Market Size and Forecast

  • 18.1 Overview
  • 18.2 Market Revenue, by Product Type (2015-2030)
    • 18.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 18.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 18.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 18.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 19. Italy Market Size and Forecast

  • 19.1 Overview
  • 19.2 Market Revenue, by Product Type (2015-2030)
    • 19.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 19.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 19.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 19.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 20. Spain Market Size and Forecast

  • 20.1 Overview
  • 20.2 Market Revenue, by Product Type (2015-2030)
    • 20.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 20.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 20.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 20.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 21. China Market Size and Forecast

  • 21.1 Overview
  • 21.2 Market Revenue, by Product Type (2015-2030)
    • 21.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 21.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 21.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 21.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 22. Japan Market Size and Forecast

  • 22.1 Overview
  • 22.2 Market Revenue, by Product Type (2015-2030)
    • 22.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 22.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 22.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 22.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 23. India Market Size and Forecast

  • 23.1 Overview
  • 23.2 Market Revenue, by Product Type (2015-2030)
    • 23.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 23.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 23.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 23.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 24. Australia Market Size and Forecast

  • 24.1 Overview
  • 24.2 Market Revenue, by Product Type (2015-2030)
    • 24.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 24.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 24.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 24.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 25. South Korea Market Size and Forecast

  • 25.1 Overview
  • 25.2 Market Revenue, by Product Type (2015-2030)
    • 25.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 25.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 25.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 25.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 26. Brazil Market Size and Forecast

  • 26.1 Overview
  • 26.2 Market Revenue, by Product Type (2015-2030)
    • 26.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 26.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 26.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 26.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 27. Mexico Market Size and Forecast

  • 27.1 Overview
  • 27.2 Market Revenue, by Product Type (2015-2030)
    • 27.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 27.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 27.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 27.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 28. Saudi Arabia Market Size and Forecast

  • 28.1 Overview
  • 28.2 Market Revenue, by Product Type (2015-2030)
    • 28.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 28.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 28.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 28.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 29. South Africa Market Size and Forecast

  • 29.1 Overview
  • 29.2 Market Revenue, by Product Type (2015-2030)
    • 29.2.1 Drugs Market Revenue, by Type (2015-2030)
      • 29.2.1.1 Antidepressants drugs market revenue, by type (2015-2030)
    • 29.2.2 Drugs Market Revenue, by Disorder Type (2015-2030)
    • 29.2.3 Drugs Market Revenue, by Distribution Channel (2015-2030)

Chapter 30. Competitive Landscape

  • 30.1 List of Market Players and Their Offerings
  • 30.2 Product Benchmarking
  • 30.3 Recent Strategic Developments of Key Players
    • 30.3.1 Product Launches and Approvals
    • 30.3.2 Mergers and Acquisitions
    • 30.3.3 Others

Chapter 31. Company Profiles

  • 31.1 Novartis AG
    • 31.1.1 Business Overview
    • 31.1.2 Product and Service Offerings
    • 31.1.3 Key Financial Summary
  • 31.2 Pfizer Inc.
    • 31.2.1 Business Overview
    • 31.2.2 Product and Service Offerings
    • 31.2.3 Key Financial Summary
  • 31.3 Bristol-Myers Squibb Company
    • 31.3.1 Business Overview
    • 31.3.2 Product and Service Offerings
    • 31.3.3 Key Financial Summary
  • 31.4 Johnson & Johnson
    • 31.4.1 Business Overview
    • 31.4.2 Product and Service Offerings
    • 31.4.3 Key Financial Summary
  • 31.5 Merck & Co. Inc.
    • 31.5.1 Business Overview
    • 31.5.2 Product and Service Offerings
    • 31.5.3 Key Financial Summary
  • 31.6 AbbVie Inc.
    • 31.6.1 Business Overview
    • 31.6.2 Product and Service Offerings
    • 31.6.3 Key Financial Summary
  • 31.7 Eli Lilly and Company
    • 31.7.1 Business Overview
    • 31.7.2 Product and Service Offerings
    • 31.7.3 Key Financial Summary
  • 31.8 GlaxoSmithKline plc
    • 31.8.1 Business Overview
    • 31.8.2 Product and Service Offerings
    • 31.8.3 Key Financial Summary
  • 31.9 Sanofi
    • 31.9.1 Business Overview
    • 31.9.2 Product and Service Offerings
    • 31.9.3 Key Financial Summary
  • 31.10 H. Lundbeck A/S
    • 31.10.1 Business Overview
    • 31.10.2 Product and Service Offerings
      • 31.10.2.1 Marketed products
      • 31.10.2.2 Pipeline products
    • 31.10.3 Key Financial Summary
  • 31.11 Mylan N.V.
    • 31.11.1 Business Overview
    • 31.11.2 Product and Service Offerings
    • 31.11.3 Key Financial Summary
  • 31.12 Cipla Ltd.
    • 31.12.1 Business Overview
    • 31.12.2 Product and Service Offerings
    • 31.12.3 Key Financial Summary
  • 31.13 Glenmark Life Sciences Limited
    • 31.13.1 Business Overview
    • 31.13.2 Product and Service Offerings
    • 31.13.3 Key Financial Summary
  • 31.14 Lupin Limited
    • 31.14.1 Business Overview
    • 31.14.2 Product and Service Offerings
    • 31.14.3 Key Financial Summary
  • 31.15 Amneal Pharmaceuticals Inc.
    • 31.15.1 Business Overview
    • 31.15.2 Product and Service Offerings
    • 31.15.3 Key Financial Summary
  • 31.16 AstraZeneca plc
    • 31.16.1 Business Overview
    • 31.16.2 Product and Service Offerings
      • 31.16.2.1 Marketed products
      • 31.16.2.2 Pipeline products
    • 31.16.3 Key Financial Summary
  • 31.17 Sun Pharmaceutical Industries Ltd.
    • 31.17.1 Business Overview
    • 31.17.2 Product and Service Offerings
    • 31.17.3 Key Financial Summary
  • 31.18 Intas Pharmaceuticals Ltd.
    • 31.18.1 Business Overview
    • 31.18.2 Product and Service Offerings
    • 31.18.3 Key Financial Summary
  • 31.19 Sumitomo Dainippon Pharma Co. Ltd.
    • 31.19.1 Business Overview
    • 31.19.2 Product and Service Offerings
    • 31.19.3 Key Financial Summary

Chapter 32. Appendix

  • 32.1 Abbreviations
  • 32.2 Sources and References
  • 32.3 Related Reports